Design and synthesis of m1-selective muscarinic agonists: (R)-(-)-(Z)- 1-azabicyclo[2.2.1]heptan-3-one, O-(3-(3'-methoxyphenyl)-2-propynyl)-oxime maleate (CI-1017), a functionally m1-selective muscarinic agonist

Journal of Medicinal Chemistry

Volumn 41, Issue 14, 1998, Pages 2524-2536

  Tecle, Halle ^a   Barrett, Stephen D ^a   Lauffer, David J ^a   Augelli Szafran, Corinne ^a   Brann, Mark R ^b   Callahan, Michael J ^a   Caprathe, Bradley W ^a   Davis, Robert E ^a   Doyle, Patricia D ^a   Eubanks, David ^b   Lipiniski, William ^a   Mirzadegan, Tara ^a   Moos, Walter H ^a   Moreland, D W ^a   Nelson, Carrie B ^a   Pavia, Michael R ^a   Raby, Charlotte ^a   Schwarz, Roy D ^a   Spencer, Carolyn J ^a   Thomas, Anthony J ^a   Jaen, Juan C ^a   more..

^a PFIZER INC   (United States)

^b ACADIA PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 AZABICYCLO[2.2.1]HEPTAN 3 ONE O [3 (3' METHOXYPHENYL) 2 PROPYNYL]OXIME MALEATE; 1 AZABICYCLO[2.2.1]HEPTAN 3 ONE O [3 (3' METHOXYPHENYL) 2 PROPYNYL]OXIME OXALATE; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC RECEPTOR; PD 142505; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHO CELL; COGNITIVE DEFECT; DRUG DESIGN; DRUG EFFICACY; DRUG SYNTHESIS; ENANTIOMER; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; TASK PERFORMANCE;

3T3 CELLS; ADENYLATE CYCLASE; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; CHO CELLS; CRICETINAE; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; INOSITOL PHOSPHATES; MALE; MEMORY; MICE; MUSCARINIC AGONISTS; OXIMES; RATS; RECEPTOR, MUSCARINIC M1; RECEPTORS, MUSCARINIC; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 14444282865     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960683m     Document Type: Article

References (56)

1. Whitehouse, P.; Price, D.; Struble, R.; Clark, A.; Coyle, J.; DeLong, M. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982, 215, 1237-1239.
2. Davies, P.; Maloney, A. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976, 2, 1403.
3. Perry, E. K.; Tomlinson, B. E.; Blessed, G.; Bergmann, K.; Gibson. P.; Perry, R. H. Correlation of cholinergic abnormalities with senile plaques and mental test scores in dementia. Br. Med. J. 1978, 2, 1457-1459.
4. Christie, J. E.; Shering, A.; Ferguson, J.; Glen. A. L. Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. Br. J. Psychiatry 1981, 138, 46-50.
5. Brinkman, S. D.; Gershon, S. Measurement of cholinergic drug effects on memory in Alzheimer's disease. Neurobiol. Aging 1983, 4, 139-145.
6. Wettstein, A.; Spiegel, R. Clinical trials with the cholinergic drug RS 86 in Alzheimer's disease (AD) and senile dementia of the Alzheimer type (SDAT). Psychopharmacology (BcHin) 1984, 84, 572-573.
7. Bruno, G.; Mohr, E.; Gillespie, M.; Fedio, P.; Chase, T. N. Muscarinic agonist therapy of Alzheimer'e disease: A clinical trial of RS-86. Arch. Neurol, 1986, 43, 659-661.
8. Davis, K. L.; Hollander, E.; Davidson, M.; Davis, B. M.; Mohs, R. C.; Horvath, T. B. Induction of depression with oxotremorine in patients with Alzheimer's disease. Am. J. Psychiatry 1987, 144, 468-471.
9. Mouradian, M. M.; Mohr, E.; Williams, J. A.; Chase, T. N. No response to high-dose muscarinic agonist therapy in Alzheimer's disease. Neurology 1988, 38, 606-608.
10. Tariot, P. N.; Cohen, R. M.; Welkowotz, J. A.; Sunderland, T.; Newhouse, P. A.; Murphy, D. L.; Weigartner, H. Multiple-dose arecoline infusions in Alzheimer's disease. Arch. Gen. Psychiatry 1988, 45, 901-905.
11. Raffaele, K. C.; Berardi, A.; Morris, P. P.; Asthana, S.; Haxby, J. V.; Schapiro, M. B.; Rapoport, S. I.; Soncrant, T. T. Effects of acute infusion of the muscarinic cholinergic agonist arecoline on verbal memory and visuo-spatial function in dementia of the Alzheimer type. Prog. Neuropsychopharmacol. Biol. Psychiatry 1991, 15, 643-648.
12. Volger, B. W. Alternatives in the treatment of memory loss in patients with Alzheimer's disease. Clin. Pharmacol. 1991, 10, 447-456.
13. Raffaele, K. C.; Berardi, A.; Asthana, S.; Morris, P. P.; Haxby, J. V.; Soncrant, T. T. Effects of long-term continuous infusion of the muscarinic cholinergic agonist arecoline on verbal memory in dementia of the Alzheimer type. Psychopharmacol. Bull 1991, 27, 315-319.
14. Soncrant, T. T.; Raffaele, K. C.; Asthana, S.; Berardi, A.; Morris, P. P.; Haxby, J. V. Memory improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimer's diseases. Psychopharmacology 1993, 112, 421-427.
15. Jones, S. V. P.; Levey, A. I.; Weiner, D. M.; Ellis, J.; Novotny, E.; Yu, S. H.; Dorje, F.; Wess, J.; Brann, M. R. Muscarinic acetylcholine receptors. In Molecular Biology of G-Protein Receptors; Brann, M. R., Ed.; Birkhauser: Boston, 1992; pp 170-197.
16. Baker, R.; Saunders J. Annu. Rep. Med. Chem. 1989, 24, 31-40 and references therein.
17. Goyal, R. K. Muscarinic receptor subtypes, physiology and clinical implications. N. Engl J. Med. 1989, 321, 1022-1029.
18. Levey, A. I. Immunological localization of ml-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci. 1993, 52, 441-448.
19. Kumar, V.; Calache, M. Treatment of Alzheimer's disease with cholinergic drugs. Int. J. Clin. Pharmacol. Ther. Toxicol. 1991, 29, 23-27.
20. Schwarz, R. D.; Callahan, M. J.; Davis, R. E.; Jaen, J. C.; Lipinski, W.; Raby, C.; Spencer, C. J.; Tecle, H. Selective muscarinic agonists for Alzheimer's disease treatment. In Alzheimer's Disease; Giacohini, E., Becker, R. E., Ed.; Birkhaeuser, Boston, 1994; pp 224-228.
21. Tecle, H.; Lauffer, D. J.; Mirzadegan, T.; Moos, W. H.; Moreland, D. W.; Pavia, M. R.; Schwarz, R. D.; Davis, R. E. Synthesis and SAR of bulky 1-azabicyclo[2.2.1]-3-one oximes as muscarinic receptor subtype selective agonists. Life Sci. 1993, 52, 505.
22. Buckley, N. J.; Bonner, T. I.; Buckley, C. M.; Brann, M. R. Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol. Pharmacol 1989, 35, 469-476.
23. Doerje, F.; Wess, J.; Lambrecht G.; Tacke, R.; Mutschler, E.; Brann M. R. J. Antagonist binding profiles of five cloned human muscarinic receptor subtypes. Pharmacol Exp, Ther. 1991, 256, 727-733.
24. Bolden, C.; Cusack, B.; Richelson, E. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J. Pharmacol. Exp. Ther. 1992, 517, 576-580.
25. Buckley, N. J. Molecular pharmacology of cloned muscarinic receptors. In Transmembrane Signaling, Intercellular Messengers and Implications for Drug Development, Nahorski, S. R., Ed.; John Wiley & Sons: New York, 1990; pp 11-31.
26. Venter, J. C.; Fraser, C. M. Molecular biology of receptors and drug design. In Drug Discovery Technologies; Clark, C. R., Moos, W. H., Eds.; Ellis Horwood: Chichester, 1990; pp 231-255.
27. Bonner, T. I.; Buckley, N. J.; Young, A. C.; Brann, M. R. Identification of a family of muscarinic acetylcholine receptor genes. Science 1987, 237, 527-532.
28. Hulme, E. C.; Birdsall, N. J. M.; Buckley, N. J. Muscarinic receptor subtypes. Annu. Rev. Pharmacol Toxicol 1990, 30, 633-673.
29. Saunders, J.; MacLeod, A. M.; Merchant, K.; Showell, G. A.; Snow, R. J.; Street, L. J.; Baker, R. Ester bioisosteres: Synthesis of oxadiazolyl-l-azabicyclo[2..2..1]heptanes as muscarinic agonists. J. Chem. Soc., Chem. Commun. 1988, 1618-1619.
30. Street, L. J.; Baker, R.; Book, T.; Kneen, C. O.; MacLeod, A. M.; Merchant, K. J.; Showell, G. A.; Saunders, J.; Herbert, R. H.; et al. Synthesis and biological activity of 1,2,4-oxadiazole derivatives: highly potent and efficacious agonists for cortical muscarinic receptors. J. Med. Chem, 1990, 33, 2690-2697.
31. Orlek, B. S.; Blaney, F. E.; Brown, F., Clark, M. S. G.; Hadley, M. S.; Hatcher, J.; Riley, G. J.; Rosenberg, H. E.; Wadsworth, H. J.; Wyman, P. Comparison of azabicyclic esters and oxadiazoles as Uganda for the rauscarinic receptor. J. Med. Chem. 1991, 34, 2726-2735.
32. Bromidge, Steven M.; Brown, Frank; Cassidy, Frederick; Clark, Michael S. G.; Dabbs, Steven; Hadley, Michael S.; Loudon, Julia M.; Orlek, Barry S.; Riley, Graham J. Design and synthesis of azabicyclic muscarinic agonists incorporating an oxime ether functionality. Bioorg. Med. Chem. Lett. 1992, 2, 787-90.
33. Street, L. J.; Baker, R.; Book, T.; Reeve, A. J.; Saunders, J.; Willson, T.; Marwood, R. S.; Patel, S.; Freedman, S. B. Synthesis and muscarinic activity of quinuclidinyl- and (1-azanorbornyl)-pyrazine derivatives. J. Med. Chem. 1992, 35, 295-305.
34. MacLeod, A. M.; Baker, R.; Herbert, R.; Lewis, R. T.; Medarde, M.; Street, L. J. Synthesis of azanorbomyl-spirodioxolanea related to the muscarinic agonist AF30. Tetrahedron Lett. 1992, 33, 4217-4220.
35. Showell, G. A.; Baker, R.; Davis, J.; Hargreaves, R.; Freedman, S. B.; Hoogsteen, K.; Patel, S.; Snow, R. J. Synthesis and in vitro biological profile of all four isomers of the potent muscarinic agonist 3-(3-methyl-1,2,4-oxadiazol-5-yl)l-azabicyclo[2.2.1]-heptane, J. Med. Chem. 1992, 35, 911-916.
36. Jenkins, S. M.; Wads worth, H. J.; Bromidge, S.; Orlek, B. S.; Wyman, P. A.; Riley, G. J.; Hawkins, J. Substituent variation in azabicyclic triazole- and tetrazole-based muscarinic receptor ligands. J. Med. Chem. 1992, 35, 2392-2406.
37. Baker, R.; Showell, G. A.; Street, L. J.; Saunders, J.; Hoogsteen, K.; Freedman, S. B.; Hargreaves, R. J. Synthesis, physicochemical and conformational properties of (3R,4R)-3-(cyclopropyl-1,2,4-oxadiazol-5-yl)-l-azabicyclo[2.2.1]heptane, a novel M1 selective muscarinic partial agonist. J. Chem. Soc., Chem. Commun. 1992, 817-819.
38. Pombo-Villar, E.; Wiederhold, K. H.; Mengod, G.; Palacios, J. M.; Supavilai, P.; Boddeke, H. W. G. M. Stereoisomerism and muscarinic receptor agonists: Synthesis and effects of the stereoisomers of 3-[5-(3-amino-1,2,4-oxadiazol)yl]-1-azabicyclo-[2.2.1]heptane. Eur. J. Pharmacol Mol. Pharmacol. Sect. 1992, 226, 317-325.
39. Houghton, P. G.; Humphrey, G. R.; Kennedy, D. J.; Roberts, D. C.; Wright, S. H. B. Enantiospecific synthesis of the (4R)-1-azabicyclo[2.2.1]heptane ring system. J. Chem. Soc., Perkin Trans. 1 1993, 1421-1424.
40. Ward, J. S.; Merrit, L.; Calligaro, D. O.; Bymaster, F. P.; Shannon, H. E.; Sawyer, B. D.; Mitch, C. H.; Deeter, J. B.; Peters, S. C.; et al. Functionally selective M1 muscarinic agonists. 3. Side chain and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles. J. Med. Chem. 1995, 38, 3469-3481.
41. Brandsma, L.; Preparative Acetylenic Chemistry; Elsevier: Amsterdam, 1988.
42. Bolesterli J.; Eggnauer U.; Pombo-Villar, E.; Weber, H. P.; Walkinshaw, M.; Gould, R. O. Absolute configuration of 3-substituted 1-azabicyclo[2.2.1]heptanes. Helv. Chim. Acta 1992, 75, 507-512.
43. Barrett, S. D.; Tecle, H.; Thomas, A. J.; Caprathe, B. W.; Lauffer, D. J.; Jaen, J. C. Abstract of papers, 209th National Meeting of the American Chemical Society, Anaheim, CA; American Chemical Society: Washington, D. C., 1995; MEDI 076.
44. 3H]-cis-methyldioxolane. J. Pharmacol. Exp. Ther. 1984, 229, 747-755.
45. 3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. I. Characterization and regulation of agonist binding to putative miucarinic subtypes. J. Pharmacol. Exp. Ther. 1986, 237, 411-418.
46. Tecle, H.; Bergmeier, S.; Moos, W.; Hershenson, F.; Coughenour, L.; Davis, R.; Schwarz, R.; Moreland, D.; Dudley, D. Abstract of papers, 197th National Meeting of the American Chemical Society, Dallas, TX; American Chemical Society; Washington, D. C., 1989; MEDI-47.
47. Schwarz, R. D.; Davis, R. E.; Jaen, J. C.; Spencer, C. J.; Tecle, H.; Thomas A. J. Characterization of muscarinic agonists in recombinant cell lines. Life Sci. 1993, 52, 465-472.
48. Ringdal, B. Structural determinants of muscarinic agonist activity. In The Muscarinic Receptors: Brown, J. H., Ed.; The Humana Press: Clifton, NJ, 1989; pp 151-218 and references therein.
49. McConnell, H. M.; Owicki, J. C.; Parce, J. W.; Miller, D. L.; Baxter, G. T.; Wanda, H. G.; Pitchford, S. The Cytosensor microphysiometer: biological applications of silicon technology. Science 1992, 257, 1906-1912.
50. Braeuner-Osborne, H.; Ebert, B.; Brann, M. R.; Falch, E.; Krogsgaard-Larsen, P. Annulated Heterocyclic Bioisosteres of Norarecoline. Synthesis and Molecular Pharmacology at Five Recombinant Human Muscarinic Acetylcholine Receptors. J. Med. Chem. 1995, 35, 2188-2195.
51. Braeuner-Osborne, H.; Brann, M. R. Pharmacology of muscarinic acetylcholine receptor subtypes (m1-m5): high throughput assays in mammalian cells. EUT. J. Pharmacol, 1996, 295, 93102.
52. Jaen, J.; Barrett, S.; Brann. M.; Callahan, M.; Davis, R.; Doyle, P.; Eubanks, D.; Lauffer, D.; Lauffer, L.; Lipiniski, W.; Moreland, D.; Nelson, C.; Raby, C.; Schwarz, R.; Spencer, C.; Tecle, H. In vitro and in vivo evaluation of the subtype-selective muscarinic agonist CI-1017, Life Sci. 1995, 56, 845-852.
53. Davis, R.; Raby, C; Callahan, M., J.; Lipinski, W.; Schwarz, R.; Dudley, D., T.; Lauffer, D.; Reece, P.; Jaen, J.; Tecle H. Subtype selective muscarinic agonists: potential therapeutic agents for Alzheimer's disease. In Cholinergic Function and Dysfunction, Progress in Brain Research; Cuello, C. A., Ed.; Elsevier: Amsterdam, 1993; pp 439-445.
54. Symons, J. P.; Davis, R. E.; Marriot, J. G. Water-maze learning and effects of cholinergic drugs in mouse strains with high and low hippocampal pyramidal cell counts. Life Sci. 1988, 42, 375-383.
55. Whishaw, I. Q.; O'Connor, W. T.; Dunnett, S. B. Disruption of central cholinergic systems in the rat basal forebrain lesions or atropine: effects on feeding, sensorimotor behavior, locomotor activity and spatial navigation. Behav. Brain Res. 1985, 17, 103-115.
56. Nabeshima, T.; Ogawa, S. I.; Nishimura, H.; Fuji, K.; Kameyama, T.; Sasaki, Y. Staurosporine facilitates recovery from the basal forebrain-lesion-induced impairment of learning and deficit of cholinergic neuron in rats. J. Pharmacol. Exp. Ther. 1991, 257, 562-566.